CONMED (NYSE:CNMD) Posts Quarterly Earnings Results, Beats Estimates By $0.04 EPS

CONMED (NYSE:CNMD) issued its earnings results on Wednesday. The company reported $1.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.00 by $0.04, FiscalAI reports. CONMED had a return on equity of 14.03% and a net margin of 5.36%. The firm had revenue of $335.56 million for the quarter, compared to analysts’ expectations of $336.28 million. During the same quarter last year, the business earned $1.08 earnings per share. The company’s revenue was down .7% compared to the same quarter last year.

Here are the key takeaways from CONMED’s conference call:

• Q3 performance exceeded expectations: Organic constant-currency revenue grew 6.7%, while adjusted EPS of $1.04 surpassed the high end of management’s prior outlook.
• Growth was broad-based across the portfolio, led by AirSeal, direct Buffalo Filter smoke evacuation, and BioBrace. General surgery grew 6.4% and orthopedics grew 7.2% organically, with particularly strong international performance.
• Management highlighted significant longer-term growth opportunities, including AirSeal’s low penetration in laparoscopic procedures, expanding smoke-evacuation legislation across 23 states, and new BioBrace regulatory clearance in Brazil.
• Management narrowed 2026 organic constant-currency revenue growth guidance to 5%–5.5% from 5%–6%, citing a more measured sequential improvement outlook and the expectation that favorable international distributor-order timing in Q3 will not repeat in Q4.
• Higher borrowing costs following the debt refinancing increased Q3 interest expense to $10.5 million from $6.3 million, while U.S. orthopedic sales declined 1.7% and OEM smoke-evacuation demand remained variable.

CONMED Trading Down 2.8%

CNMD traded down $1.29 during trading on Friday, hitting $44.43. 134,212 shares of the stock traded hands, compared to its average volume of 504,672. The firm has a market capitalization of $1.33 billion, a P/E ratio of 18.34, a price-to-earnings-growth ratio of 2.09 and a beta of 0.94. CONMED has a 12-month low of $31.44 and a 12-month high of $53.66. The firm has a 50-day moving average of $47.20 and a 200 day moving average of $41.45. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.48 and a quick ratio of 0.69.

Trending Headlines about CONMED

Here are the key news stories impacting CONMED this week:

• Positive Sentiment: CONMED reported third-quarter adjusted earnings of $1.04 per share, exceeding the $1.00 analyst consensus. The company also raised the low end of its full-year 2026 EPS outlook, now expecting $4.54–$4.61 versus a $4.54 consensus estimate. CONMED Q3 Profit Rises, Updates 2026 Guidance
• Positive Sentiment: JPMorgan raised its CONMED price target from $45 to $50, while retaining a neutral rating. Wells Fargo also increased its target from $46 to $49 and maintained an equal-weight rating, indicating improved valuation support but limited conviction in significant outperformance. JPMorgan CONMED price-target update Wells Fargo CONMED price-target update
• Neutral Sentiment: CONMED reaffirmed a 2026 revenue outlook of approximately $1.4 billion, matching the consensus estimate. The guidance update suggests execution remains broadly on track, but it does not provide a major upward catalyst. CONMED third-quarter results and guidance
• Negative Sentiment: Third-quarter revenue of $335.56 million was slightly below the $336.28 million consensus and declined 0.7% year over year. Earnings also fell from $1.08 per share in the prior-year quarter, highlighting soft top-line momentum despite the EPS beat. CONMED Q3 earnings beat estimates

Wall Street Analysts Forecast Growth

CNMD has been the topic of several analyst reports. JPMorgan Chase & Co. boosted their price target on shares of CONMED from $45.00 to $50.00 and gave the stock a “neutral” rating in a research report on Thursday. Needham & Company LLC restated a “hold” rating on shares of CONMED in a research report on Monday, July 13th. Piper Sandler reiterated a “neutral” rating and set a $45.00 price objective (up from $39.00) on shares of CONMED in a research report on Thursday, July 30th. BMO Capital Markets started coverage on CONMED in a research report on Wednesday, July 8th. They set a “market perform” rating and a $36.00 price objective for the company. Finally, Weiss Ratings raised CONMED from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, October 21st. Seven investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Reduce” and a consensus price target of $44.00.

CONMED Company Profile

CONMED Corporation is a medical technology company that develops, manufactures, and sells surgical devices and related equipment. Its products are used by hospitals, ambulatory surgery centers, and other healthcare providers in orthopedic and general surgery procedures.

The company’s orthopedic portfolio includes arthroscopy systems, powered surgical instruments, sports medicine products, tissue ablation systems, implants, and related accessories. Its general surgery offerings include electrosurgical equipment, insufflation systems, smoke evacuation products, surgical visualization technologies, and devices used in minimally invasive procedures.

Founded in 1970, CONMED serves healthcare customers through direct sales and distribution channels in the United States and international markets.